NASDAQ:PRTA - Prothena Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.38
  • Forecasted Upside: -3.06 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.76 (1.58%)

This chart shows the closing price for PRTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prothena Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTA

Analyst Price Target is $47.38
▼ -3.06% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Prothena in the last 3 months. The average price target is $47.38, with a high forecast of $62.00 and a low forecast of $29.00. The average price target represents a -3.06% upside from the last price of $48.87.

This chart shows the closing price for PRTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Prothena. This rating has held steady since December 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/18/2021Bank of AmericaUpgradeUnderperform ➝ Neutral$12.00 ➝ $49.00High
6/11/2021Royal Bank of CanadaBoost Price TargetOutperform$28.00 ➝ $50.00Medium
6/10/2021HC WainwrightBoost Price TargetBuy$33.00 ➝ $58.00High
6/8/2021OppenheimerBoost Price TargetPositive ➝ Outperform$45.00 ➝ $54.00High
6/8/2021Cantor FitzgeraldBoost Price TargetOverweight$43.00 ➝ $62.00High
6/1/2021OppenheimerBoost Price TargetOutperform$40.00 ➝ $45.00High
5/26/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageBuy$39.00High
5/26/2021CitigroupInitiated CoverageBuyHigh
5/12/2021OppenheimerBoost Price TargetOutperform$35.00 ➝ $40.00High
3/15/2021Jefferies Financial GroupBoost Price TargetBuy$30.00 ➝ $38.00High
3/2/2021OppenheimerReiterated RatingBuy$35.00Medium
2/26/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$14.00 ➝ $28.00Medium
2/12/2021Jefferies Financial GroupUpgradeHold ➝ Buy$15.00 ➝ $30.00Low
2/4/2021HC WainwrightBoost Price TargetBuy$22.00 ➝ $33.00Low
2/2/2021OppenheimerBoost Price TargetOutperform$25.00 ➝ $35.00Low
2/2/2021BTIG ResearchUpgradeNeutral ➝ Buy$29.00Low
12/10/2020OppenheimerBoost Price Target$20.00 ➝ $25.00Low
12/7/2020HC WainwrightInitiated CoverageBuy$22.00Low
10/21/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$20.00 ➝ $24.00High
9/13/2020OppenheimerReiterated RatingBuy$18.00High
7/8/2020OppenheimerUpgradeMarket Perform ➝ Outperform$16.00High
5/13/2020OppenheimerReiterated RatingHoldHigh
5/10/2020NomuraReiterated RatingBuy$19.00High
4/23/2020OppenheimerReiterated RatingHoldLow
1/1/2020Nomura SecuritiesReiterated RatingBuy$19.00Low
12/22/2019Evercore ISIReiterated RatingBuy$14.00High
11/27/2019Evercore ISIUpgradeIn-Line ➝ OutperformLow
11/19/2019Evercore ISIUpgradeIn-Line ➝ Outperform$14.00High
5/31/2019BarclaysReiterated RatingSell$9.00Low
5/16/2019Cantor FitzgeraldReiterated RatingOverweightHigh
3/4/2019Cantor FitzgeraldInitiated CoverageOverweight$13.77High
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/11/2018OppenheimerReiterated RatingHoldHigh
8/8/2018Cantor FitzgeraldReiterated RatingBuy$18.00Low
6/15/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$14.00 ➝ $18.00High
5/25/2018OppenheimerReiterated RatingHoldLow
5/21/2018BarclaysDowngradeEqual Weight ➝ Underweight$12.00High
5/9/2018OppenheimerReiterated RatingHoldHigh
4/24/2018Nomura SecuritiesLower Price TargetBuy ➝ Buy$87.00 ➝ $19.00High
4/24/2018WedbushLower Price TargetNeutral$46.00 ➝ $13.00High
4/24/2018BTIG ResearchDowngradeBuy ➝ Neutral$77.00High
4/24/2018Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Buy$78.00 ➝ $16.00High
4/24/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$69.00 ➝ $14.00High
4/23/2018OppenheimerDowngradeOutperform ➝ HoldHigh
4/23/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$87.00High
4/23/2018BarclaysDowngradeOverweight ➝ Equal WeightHigh
4/23/2018Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
4/5/2018BarclaysLower Price TargetOverweight ➝ Overweight$70.00 ➝ $50.00Medium
3/21/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyHigh
3/21/2018Cantor FitzgeraldReiterated RatingOverweight$69.00High
3/21/2018OppenheimerSet Price TargetBuy$70.00High
2/15/2018OppenheimerSet Price TargetBuy$70.00High
2/4/2018Cantor FitzgeraldReiterated RatingBuy$65.00High
12/20/2017Cantor FitzgeraldReiterated RatingBuy$65.00Medium
12/4/2017OppenheimerSet Price TargetBuy$70.00High
11/20/2017WedbushDowngradeOutperform ➝ Neutral$75.00 ➝ $55.00N/A
11/9/2017OppenheimerReiterated RatingBuy$70.00N/A
10/23/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$73.00N/A
10/2/2017Jefferies Financial GroupReiterated RatingBuy$100.00Low
10/2/2017SunTrust BanksReiterated RatingBuy$75.00Low
10/1/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
9/29/2017Royal Bank of CanadaReiterated RatingBuyHigh
9/29/2017BTIG ResearchLower Price TargetBuy ➝ Buy$80.00 ➝ $77.00High
9/28/2017Cantor FitzgeraldReiterated RatingBuy$79.00Medium
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$87.00High
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$83.00High
7/10/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$100.00Medium
7/6/2017OppenheimerReiterated RatingOutperform$70.00Low
5/19/2017BTIG ResearchInitiated CoverageBuy$80.00High
5/16/2017Piper Jaffray CompaniesReiterated RatingBuyMedium
5/11/2017OppenheimerSet Price TargetBuy$70.00Low
4/12/2017Cantor FitzgeraldInitiated CoverageOverweight$86.00High
4/12/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$69.00Medium
4/6/2017OppenheimerSet Price TargetBuy$70.00Low
4/3/2017WedbushReiterated RatingOutperform$77.00High
3/22/2017OppenheimerReiterated RatingBuyLow
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$87.00N/A
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
2/15/2017WedbushReiterated RatingOutperform$77.00N/A
12/20/2016SunTrust BanksInitiated CoverageBuy$75.00N/A
12/6/2016WedbushReiterated RatingOutperform$77.00N/A
11/10/2016WedbushReiterated RatingOutperform$77.00N/A
11/3/2016Deutsche Bank AktiengesellschaftInitiated CoverageBuy$73.00N/A
10/31/2016WedbushReiterated RatingOutperform$77.00N/A
9/27/2016Credit Suisse GroupReiterated RatingBuy$65.00N/A
9/26/2016WedbushReiterated RatingOutperform$77.00N/A
9/11/2016Credit Suisse GroupReiterated RatingBuy$65.00N/A
8/4/2016BarclaysBoost Price TargetOverweight$60.00 ➝ $70.00N/A
8/4/2016UBS GroupReiterated RatingBuy$73.00N/A
8/3/2016WedbushReiterated RatingOutperform$77.00N/A
7/18/2016Royal Bank of CanadaReiterated RatingOutperform$95.00N/A
7/12/2016Credit Suisse GroupReiterated RatingBuyN/A
7/5/2016WedbushReiterated RatingOutperform$77.00N/A
(Data available from 6/24/2016 forward)
Prothena logo
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Read More

Today's Range

Now: $48.87
Low: $48.32
High: $53.73

50 Day Range

MA: $31.24
Low: $21.63
High: $57.65

52 Week Range

Now: $48.87
Low: $9.39
High: $59.74


696,615 shs

Average Volume

452,533 shs

Market Capitalization

$2.16 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Prothena?

The following sell-side analysts have issued stock ratings on Prothena in the last twelve months: Bank of America Co., BTIG Research, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for PRTA.

What is the current price target for Prothena?

8 Wall Street analysts have set twelve-month price targets for Prothena in the last year. Their average twelve-month price target is $47.38, suggesting a possible downside of 3.1%. Cantor Fitzgerald has the highest price target set, predicting PRTA will reach $62.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $29.00 for Prothena in the next year.
View the latest price targets for PRTA.

What is the current consensus analyst rating for Prothena?

Prothena currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRTA will outperform the market and that investors should add to their positions of Prothena.
View the latest ratings for PRTA.

What other companies compete with Prothena?

How do I contact Prothena's investor relations team?

Prothena's physical mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company's listed phone number is 011-353-1236-2500 and its investor relations email address is [email protected] The official website for Prothena is